Surufatinib Combined with TAS-102 As a Late-Line Therapy in Patients with Metastatic Pancreatic Cancer (mpdac): Updated Results of a Single-Arm, Phase II Trial.

Dong-Sheng Zhang, Yun-Xin Lu, Fu-Rong Liu, Bing Bai,Yang Zhang, Zhiqiang Wang,Yu Liu, Jian-Wen Chen,Yu-Hong Li,Feng-Hua Wang, Gui Fang Guo,Feng Wang,Rui-Hua Xu

Journal of Clinical Oncology（2025）

Cited 0|Views3

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined